Antiestrogens, Aromatase Inhibitors, and Apoptosis in Breast Cancer

Rebecca B. Riggins, Amy H. Bouton, Minetta C. Liu, Robert Clarke

Research output: Chapter in Book/Report/Conference proceedingChapter

71 Scopus citations


Antiestrogens have been the therapeutic agents of choice for breast cancer patients whose tumors express estrogen receptors, regardless of menopausal status. Unfortunately, many patients will eventually develop resistance to these drugs. Antiestrogens primarily act by preventing endogenous estrogen from activating estrogen receptors and promoting cell growth, which can ultimately lead to tumor cell death. Understanding the mechanisms by which antiestrogens cause cell death or apoptosis is critical to our efforts to develop ways to circumvent resistance. This article focuses on antiestrogen-induced apoptosis both in vitro and in vivo. We review the clinical utility of both antiestrogens and aromatase inhibitors and their apoptogenic mechanisms in cell culture models. Among the key signaling components discussed are the roles of Bcl-2 family members, several cytokines, and their receptors, p53, nuclear factor kappa B (NFκB), IRF-1, phosphatidylinositol 3-kinase (PI3K)/Akt, and specific caspases. Finally, we discuss the evidence supporting a role for apoptotic defects in acquired and de novo antiestrogen resistance.

Original languageEnglish (US)
Title of host publicationVitamins and Hormones
EditorsGerald Litwack
Number of pages37
StatePublished - 2005
Externally publishedYes

Publication series

NameVitamins and Hormones
ISSN (Print)0083-6729


Dive into the research topics of 'Antiestrogens, Aromatase Inhibitors, and Apoptosis in Breast Cancer'. Together they form a unique fingerprint.

Cite this